Company intelligence / Profile preview
Kelun-Biotech
Chengdu, Sichuan, Chinaen.kelun-biotech.com ↗
- Ownership
- Public · 6990
- Development stage
- Commercial
01
Overview
Kelun-Biotech has built a robust pipeline of over thirty assets—including more than ten clinical-stage programs—focused on innovative biologics and small molecules for oncology and other major diseases. Its proprietary OptiDC™ ADC platform underpins several first-in-class or best-in-class candidates. Fourteen programs are in clinical development in China; two have entered US trials. Notable recent progress includes FDA IND clearance for SKB518 ADC targeting advanced solid tumors.[10] The company has established global partnerships validating its technology.[5]
- Therapeutic areas
- OncologyMetabolic DisordersImmunologyInfectious Diseases
- Modalities
- Antibody-drug conjugates (ADCs)Monoclonal antibodies (mAbs)Bispecific antibodies (bsAbs)Small molecules
- Industry
- Biotech
02
Drug pipeline
33 assets32 more assets in the full pipeline.
03
Partnerships
Merck & Co., Inc.: Exclusive license/collaboration agreement covering multiple investigational preclinical/clinical antibody-drug conjugate therapies for cancer treatment worldwide except Greater China region.Harbour BioMed Therapeutics LimitedWindward Bio AGEllipses Pharma Limited
04
Financials
- Market cap
- $13.9B
- Total revenue
- $308.5M
- Enterprise value
- $13.2B
Beyond the preview
Go deeper on Kelun-Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kelun-Biotech.